Q1 EPS Forecast for USANA Health Sciences Cut by Analyst

USANA Health Sciences, Inc. (NYSE:USNA) – Sidoti lowered their Q1 2027 EPS estimates for shares of USANA Health Sciences in a note issued to investors on Thursday, November 5th. Sidoti analyst A. Lebiedzinski now forecasts that the company will post earnings per share of $0.24 for the quarter, down from their previous forecast of $0.28. The consensus estimate for USANA Health Sciences’ current full-year earnings is $0.55 per share. Sidoti also issued estimates for USANA Health Sciences’ Q2 2027 earnings at $0.34 EPS, Q3 2027 earnings at $0.31 EPS, Q4 2027 earnings at $0.36 EPS, Q1 2028 earnings at $0.35 EPS, Q2 2028 earnings at $0.44 EPS, Q3 2028 earnings at $0.42 EPS and FY2028 earnings at $1.68 EPS.

Several other research analysts also recently commented on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, September 21st. Zacks Research cut USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 4th. Finally, Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Two equities research analysts have rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has an average rating of “Sell”.

USANA Health Sciences Stock Performance

Shares of NYSE:USNA opened at $13.10 on Monday. The firm has a market cap of $242.12 million, a PE ratio of -11.39, a price-to-earnings-growth ratio of 2.10 and a beta of 0.66. USANA Health Sciences has a 52 week low of $12.57 and a 52 week high of $23.59. The firm’s fifty day moving average is $14.57 and its 200-day moving average is $17.86.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.22). The business had revenue of $205.89 million during the quarter, compared to analyst estimates of $217.42 million. USANA Health Sciences had a negative net margin of 2.34% and a positive return on equity of 3.56%.

Institutional Investors Weigh In On USANA Health Sciences

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in USANA Health Sciences in the second quarter worth approximately $33,182,000. Pzena Investment Management LLC bought a new position in shares of USANA Health Sciences during the 2nd quarter worth approximately $25,739,000. Nantahala Capital Management LLC bought a new position in shares of USANA Health Sciences during the 2nd quarter worth approximately $17,295,080. Lazard Asset Management LLC acquired a new stake in shares of USANA Health Sciences during the 1st quarter worth approximately $1,265,000. Finally, Empowered Funds LLC acquired a new stake in shares of USANA Health Sciences during the 2nd quarter worth approximately $1,500,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc. develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands. Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.